Intellia Therapeutics (NTLA) Accumulated Expenses (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Accumulated Expenses data on file, last reported at $9.3 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $9.3 million, down 77.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.3 million (down 77.15% YoY), and the FY2025 annual result was $49.9 million, up 107.11% from the prior year.
• Accumulated Expenses slipped to $9.3 million in Q1 2026 per NTLA's latest filing, from $49.9 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $60.9 million in Q4 2022 and troughed at $9.3 million in Q1 2026.
• A 5-year average of $35.3 million and a median of $40.8 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2026: Accumulated Expenses surged 301.99% in 2023, then plunged 77.15% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $60.9 million in 2022, then sank by 56.28% to $26.6 million in 2023, then decreased by 9.54% to $24.1 million in 2024, then soared by 107.11% to $49.9 million in 2025, then slumped by 81.3% to $9.3 million in 2026.
• Business Quant data shows NTLA's Accumulated Expenses at $9.3 million in Q1 2026, $49.9 million in Q4 2025, and $40.8 million in Q3 2025.